Characterization of the Fungal Origins in the Autoimmune Polyendocrinopathy of Type 1 Compared With the Autoimmune Polyendocrinopathies of Type 2 (APECED2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03800056|
Recruitment Status : Not yet recruiting
First Posted : January 10, 2019
Last Update Posted : January 10, 2019
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Characterization of the Fungal Origins in the Autoimmune Polyendocrinopathy of Type 1 Compared With the Autoimmune Polyendocrinopathies of Type 2|
|Estimated Study Start Date :||March 2019|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2020|
Group 1 APS 1
Patients with a APS type 1 whose molecular diagnosis (mutation of the AIRE gene) has been established in the diagnosis of the disease, regardless of their mycological status (history of mycosis) or the presence of antifungal treatment.
Group 2 APS2
Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected.
- the frequency of appearance of Candida yeast strains [ Time Frame: Baseline: one session ]the frequency of appearance of Candida yeast strains found in mycological samples from both urinary and oral patients.
Biospecimen Retention: Samples With DNA
- 2x7mL EDTA tubes and 1x7 mL dry tube for the collection of DNA, plasma ans serum.
- a urine sample and an oral collection for the characterization of fungal flora
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03800056
|Contact: Marie-Christine VANTYGHEM, MD,PhD||320 44 45 17 ext +firstname.lastname@example.org|
|Principal Investigator:||Marie-Christine VANTYGHEM, MD,PhD||University Hospital, Lille|